Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations

This publication has 26 references indexed in Scilit:

• 1391P Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
  Annals of Oncology, 2023
• Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
  Lung Cancer, 2022
• Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy
  Journal of Thoracic Oncology, 2021
• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
  Annals of Oncology, 2020
• 1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
  Annals of Oncology, 2020
• Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
  Annals of Oncology, 2020
• Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
  Lung Cancer, 2019
• Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
  Lung Cancer, 2018
• Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
  Journal of Thoracic Oncology, 2016
• Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
  Journal of Thoracic Oncology, 2016